A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of MK-4305 (Suvorexant) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Suvorexant (Primary)
- Indications Delirium; Dementia; Mild cognitive impairment
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MK-4305-085
- Sponsors Merck Sharp & Dohme Corp.
- 02 Jan 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 Planned End Date changed from 20 Jan 2023 to 23 Dec 2023.
- 19 Dec 2022 Planned primary completion date changed from 20 Jan 2023 to 23 Dec 2023.